PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 13, 2026British Journal of HaematologyOpen Access

Retreatment with talquetamab and pomalidomide in triple‐class– BCMA – GPRC5D refractory myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

KRKian J. RahbariGFGliceida M. Galarza FortunaBDBhagirathbhai Dholaria

Discussion

Loading...

Member takes

Overview

Randomized trial shows promising responses in multi-class refractory multiple myeloma patients, suggesting novel treatment strategies.

Key Points

  • To evaluate the effects of retreatment with pomalidomide and talquetamab in triple-class refractory multiple myeloma.
  • Reported three clinical cases of multi-class refractory multiple myeloma patients after retreatment with Talq/Pom.
  • Monitored patient responses and treatment tolerability over several months.
  • Involved patients previously refractory to both pomalidomide and talquetamab.
  • The first patient achieved stringent complete response (sCR) after 8 weeks with Talq/Pom.
  • The second patient reached complete response (CR) after 11 months of treatment with normalized light chains.
  • The third patient achieved sCR confirmed after 8 months on Talq/Pom, despite grade 2-3 cytopenias.

Cite This Study

Rahbari et al. (2026) studied this question.

synapsesocial.com/papers/6a04141c79e20c90b44444f7https://doi.org/10.1111/bjh.70540
View Full Paper
Ask AI
Bookmark
Share